🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

RecruitingPhase 3Ages 18 Years - anyAllUkrainian Society of Clinical Oncology
NCT06755554 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph nodes; the number of postoperative complications and complications associated with the administration of ICG. Patients who meet the inclusion criteria for this study will be enrolled in the study after reviewing and signing an informed consent form. All patients will be included in one group and will receive surgical treatment in the amount of total or subtotal gastrectomy with lymphadenectomy D1, D1+, D2 or D2+. ICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Tumor spread: cT2-4a cN0-3, * cM0; * Age: 18 - 80; * Gender: men and women; * ECOG: 0 - 1; * Histologic type of tumor: Adenocarcinoma of any subtype; * Degree of differentiation: G1 - G4; * Tumor localization: cardiac region, stomach floor, stomach body, antrum, pylorus, and pyloric region of the stomach; * Tumor spread: absence of tumor invasion into adjacent structures; * No history of cancer in the last 5 years; * No previous chemotherapy, surgery or radiation treatment for another cancer (except for neoadjuvant chemotherapy for gastric cancer); * Absence of severe comorbidity restricting laparoscopic approach. Exclusion Criteria: * M1 (distant metastases); * ECOG 2 - 4; * Age over 80 and under 18; * Presence of severe comorbidities, ASA\> 3; * Patient refusal to participate in the study.
💊

What it tests

  • Endoscopic injection of Indocyanine green
📍

Where

2 sites
National Cancer Institute
Kyiv, Ukraine
National Cancer Institute
Kyiv, Ukraine
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy